1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Date not available
Admin
News Article

Zuellig Pharma Enters into Agreement with GSK

Zuellig Pharma announced that it has entered into an agreement with, GSK, to establish their first vaccine distribution hub in the Singapore.

The partnership between Zuellig Pharma Singapore and GSK entails Zuellig Pharma providing GSK with warehousing and distribution services specifically tailored to cold-chain management for its vaccines.

The launch of GSK's regional vaccine distribution hub through its strategic partnership with Zuellig Pharma marks a significant milestone with far-reaching benefits.

This collaboration will have a profound and direct impact on vaccine availability in the region, along with several other positive outcomes by significantly decrease its supply chain's overall carbon emissions compared to traditional air transport methods.

The establishment of the new vaccine distribution hub in Singapore will serve as a pivotal vaccine supply gateway into the region. The vaccine distribution hub's adoption of a sea transport model will significantly reduce its supply chain carbon footprint by at least 30% compared to air transport.